Market research
EVLO Evelo Biosciences Inc
PINK USD Healthcare
Latest close
As of 22 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 2K
- P/E ratio
- Not available
- Analyst target
- 10
- Dividend yield
- Not available
- Beta
- -28.58
Profile
Instrument facts
- Exchange
- PINK
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 2K
- P/E ratio
- Not available
- Analyst target
- 10
- Dividend yield
- Not available
- Beta
- -28.58
About
About Evelo Biosciences Inc
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriasis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Research context
Evelo Biosciences Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the EVLO discussion.
5 years, 6 months ago
Evelo Biosciences, Inc is currently in a long term uptrend where the price is trading 17.0% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Evelo Biosciences, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 28.5% to $-29M since the same quarter in the previous year.
Finally, its free cash flow grew by 0.5% to $-19M since the same quarter in the previous year.
Based on the above factors, Evelo Biosciences, Inc gets an overall score of 3/5.